[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557103":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":26,"locations":32,"responsibleParty":217,"collaborators":11,"id":219,"slug":220,"hasResults":221,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":11,"eligibilityCriteria":225,"healthyVolunteers":221,"sex":226,"minAge":227,"maxAge":11,"enrollmentInfo":228,"targetDuration":11,"studyType":231,"phases":232,"briefSummary":234,"conditions":235,"keywords":11,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},{"fullName":5,"class":6},"Stelexis BioSciences","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Eganelisib","EXPERIMENTAL",null,[13],"Drug: Eganelisib",{"label":15,"type":10,"description":11,"interventionNames":16},"Eganelisib in combination with cytarabine",[17],"Drug: Eganelisib in combination with cytarabine",[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","eganelisib will be administered as monotherapy",[9],{"type":20,"name":15,"description":24,"armGroupLabels":25,"otherNames":11},"eganelisib will be administered in combination with cytarabine",[15],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Clinical Trials Office Stelexis","CONTACT","508-543-6979","clinicaltrials@stelexis.com",[33,52,66,81,96,111,126,132,143,158,172,187,203],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-117.97729,34.13945,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":11,"email":51},"Shukaib Arslan","626-218-1133","sarslan@coh.org",{"facility":53,"status":35,"city":54,"state":55,"zip":56,"country":39,"countryCode":40,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Anshutz Cancer Pavilion","Aurora","Colorado","80045",{"type":42,"coordinates":58},[59,60],-104.83192,39.72943,{"lat":60,"lon":59},[63],{"name":64,"role":29,"phone":11,"phoneExt":11,"email":65},"Kara Grau","kara.grau@cuanschutz.edu",{"facility":67,"status":35,"city":68,"state":69,"zip":70,"country":39,"countryCode":40,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":42,"coordinates":72},[73,74],-82.45843,27.94752,{"lat":74,"lon":73},[77],{"name":78,"role":29,"phone":79,"phoneExt":11,"email":80},"Wes Mungal","813-745-0851","Wesley.Mungal@moffitt.org",{"facility":82,"status":35,"city":83,"state":84,"zip":85,"country":39,"countryCode":40,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":42,"coordinates":87},[88,89],-71.05977,42.35843,{"lat":89,"lon":88},[92],{"name":93,"role":29,"phone":94,"phoneExt":11,"email":95},"Megan Forsyth","857-215-1405","Megan_Forsyth@DFCI.Harvard.edu",{"facility":97,"status":35,"city":98,"state":99,"zip":100,"country":39,"countryCode":40,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Washington University in St Louis","St Louis","Missouri","63110",{"type":42,"coordinates":102},[103,104],-90.19789,38.62727,{"lat":104,"lon":103},[107],{"name":108,"role":29,"phone":109,"phoneExt":11,"email":110},"Na'kie Coleman-Elhasan","314-454-8708","nakie@wustl.edu",{"facility":112,"status":113,"city":114,"state":114,"zip":115,"country":39,"countryCode":40,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Memorial Sloan Kettering Cancer Center","NOT_YET_RECRUITING","New York","10065",{"type":42,"coordinates":117},[118,119],-74.00597,40.71427,{"lat":119,"lon":118},[122],{"name":123,"role":29,"phone":124,"phoneExt":11,"email":125},"Anmol Shah","646-608-2813","shaha10@mskcc.org",{"facility":112,"status":35,"city":114,"state":114,"zip":115,"country":39,"countryCode":40,"cosmosGeoPoint":127,"geoPoint":129,"contacts":130},{"type":42,"coordinates":128},[118,119],{"lat":119,"lon":118},[131],{"name":123,"role":29,"phone":124,"phoneExt":11,"email":125},{"facility":133,"status":35,"city":114,"state":114,"zip":134,"country":39,"countryCode":40,"cosmosGeoPoint":135,"geoPoint":137,"contacts":138},"Montefiore Medical Center","10466",{"type":42,"coordinates":136},[118,119],{"lat":119,"lon":118},[139],{"name":140,"role":29,"phone":141,"phoneExt":11,"email":142},"Davina Hoban","201-618-4725","davinahoban@montefiore.org",{"facility":144,"status":35,"city":145,"state":146,"zip":147,"country":39,"countryCode":40,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Cleveland Clinic","Cleveland","Ohio","44106",{"type":42,"coordinates":149},[150,151],-81.69541,41.4995,{"lat":151,"lon":150},[154],{"name":155,"role":29,"phone":156,"phoneExt":11,"email":157},"Ibraheem Al-Aref","216-442-0461","ali3@ccf.org",{"facility":159,"status":35,"city":160,"state":146,"zip":161,"country":39,"countryCode":40,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Ohio State University","Columbus","43210",{"type":42,"coordinates":163},[164,165],-82.99879,39.96118,{"lat":165,"lon":164},[168],{"name":169,"role":29,"phone":170,"phoneExt":11,"email":171},"Sarah Mayne","614-685-9573","sarah.mayne@osumc.edu",{"facility":173,"status":35,"city":174,"state":175,"zip":176,"country":39,"countryCode":40,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"MD Anderson Cancer Center","Houston","Texas","77054",{"type":42,"coordinates":178},[179,180],-95.36327,29.76328,{"lat":180,"lon":179},[183],{"name":184,"role":29,"phone":185,"phoneExt":11,"email":186},"Meagan Sachs","713-503-1589","msachs@mdanderson.org",{"facility":188,"status":35,"city":189,"state":11,"zip":190,"country":191,"countryCode":192,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"Hospital San Pedro de Alcántara","Cáceres","10003","Spain","ES",{"type":42,"coordinates":194},[195,196],-6.37224,39.47649,{"lat":196,"lon":195},[199],{"name":200,"role":29,"phone":201,"phoneExt":11,"email":202},"Juan Miguel Bergua Burgues","+34 675 699735","jmberguaburg@gmail.com",{"facility":204,"status":35,"city":205,"state":11,"zip":206,"country":191,"countryCode":192,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Hospital Universitari i Politècnic La Fe","Valencia","46026",{"type":42,"coordinates":208},[209,210],-0.37966,39.47391,{"lat":210,"lon":209},[213],{"name":214,"role":29,"phone":215,"phoneExt":11,"email":216},"Rebeca Rodriguez Veiga","+34 961 245876","rebeca_rodriguez@iislafe.es",{"type":218,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100557103","phase-1-eganelisib-as-monotherapy-and-in-combination-with-cytarabine-in-relapsedrefractory-aml-100557103",false,"NCT06533761","Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed\u002FRefractory AML","A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n* Pathological diagnosis of either: AML according to World Health Organization (WHO) 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts (acute promyelocytic leukemia is excluded but secondary AML and treatment-related AML can be included); Higher-risk (IPSS-R Intermediate, High or Very High Risk at time of study entry) myelodysplastic syndromes (HR-MDS) according to WHO 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Adequate hepatic and renal function measured within 7 days prior to the first dose of eganelisib.\n\nExclusion Criteria:\n\n* Autologous or allogeneic stem cell transplant within 6 months prior to Cycle 1 Day 1.\n* Receiving immunosuppressants (eg, cyclosporin) or systemic steroids (except for steroid use as cortisol replacement therapy in documented adrenal insufficiency).\n* Active fungal disease or uncontrolled infection of any kind; patients receiving antibiotic, antifungal or antiviral treatment must be afebrile and hemodynamically stable for \\>72 hours prior to treatment\n* WBC count \\>25 × 10\\^9\u002FL measured within 7 days prior to the first dose of eganelisib (hydroxyurea is permitted to decrease the WBC count).\n* Presence of a clinically significant non-hematologic toxicity of prior therapy that has not resolved to Grade ≤1 or Baseline, whichever is worst, as determined by NCI CTCAE v 5.0, except alopecia or skin pigmentation. Fatigue and neuropathy must have resolved to Grade ≤2.","ALL","18 Years",{"count":229,"type":230},125,"ESTIMATED","INTERVENTIONAL",[233],"PHASE1","This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed\u002Frefractory (r\u002Fr) acute myeloid leukemia (AML) or r\u002Fr higher-risk myelodysplastic syndromes (HR-MDS).\n\nThe study consists of 2 parts:\n\n* Part 1: Dose Escalation (DE) in both monotherapy and in combination.\n* Part 2: Dose Optimization",[236,237],"AML, Adult","MDS","2025-10-20",{"date":240,"type":241},"2025-10-22","ACTUAL",{"date":243,"type":241},"2025-04-28",{"date":245,"type":230},"2028-03-15",{"name":5,"class":6},13]